Analgesic, antioedematous and antioxidant activity of γ-butyrolactone derivatives in rodents

Behavioural Pharmacology

Volumn 23, Issue 4, 2012, Pages 407-416

  Salat, Kinga ^a   Librowski, Tadeusz ^a   Moniczewski, Andrzej ^a   Stanisz Wallis, Krystyna ^a   Wieckowski, Krzysztof ^a   Malawska, Barbara ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

ABTS radical cation; carrageenan induced paw oedema; inflammation; locomotor activity; motor coordination; pain; reactive oxygen species; rotarod; trolox

Indexed keywords

2,2' AZINOBIS(3 ETHYLBENZOTHIAZOLINE 6 SULFONIC ACID); ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BM 113; BM 113 A; BM 138; BM 138 A; CARRAGEENAN; GAMMA BUTYROLACTONE DERIVATIVE; MORPHINE; TROLOX C; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; HOT PLATE TEST; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MECHANICAL STIMULATION; MOUSE; NONHUMAN; PAIN; PAW EDEMA; RANDALL SELITTO MODEL; RAT; RODENT; ROTAROD TEST; WRITHING TEST;

4-BUTYROLACTONE; ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FREE RADICAL SCAVENGERS; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MOTOR ACTIVITY; PAIN; RATS; RATS, WISTAR;

EID: 84863836744     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283566042     Document Type: Article

References (43)

1. Ambriz-Tututi M, Rocha-Gonzalez HI, Cruz SL, Granados-Soto V (2009). Melatonin: a hormone that modulates pain. Life Sci 84:489-498.
2. Arts MJ, Haenen GR, Voss HP, Bast A (2004). Antioxidant capacity of reaction products limits the applicability of the Trolox Equivalent Antioxidant Capacity (TEAC) assay. Food Chem Toxicol 42:45-49. (Pubitemid 37421325)
3. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stö hr T (2007). Lacosamide: a review of preclinical properties. CNS Drug Rev 13:21-42. (Pubitemid 46697839)
4. Brü ning CA, Prigol M, Roehrs JA, Zeni G, Noguerira CW (2010). Evidence for the involvement of m-opioid and d-opioid receptors in the antinociceptive effect caused by oral administration of m-trifluoromethyl- diphenyl diselenide in mice. Behav Pharmacol 21:621-626.
5. Di Rosa M, Sorrentino L (1968). The mechanism of the inflammatory effect of carrageenin. Eur J Pharmacol 4:340-342.
6. Di Rosa M, Giroud JP, Willoughby DA (1971). Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J Pathol 104:15-29.
7. Eddy N, Leimbach D (1953). Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Ther 107:385-393.
8. Erel O (2004). A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277-285. (Pubitemid 38314881)
9. Fornai M, Natale G, Colucci R, Tuccori M, Carazzina G, Antoniolli L, et al. (2005). Mechanism of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol 372:79-87. (Pubitemid 41414048)
10. Ghaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP (2010). Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models [abstract]. Inflammopharmacology 18:169-177.
11. Guay J, Bateman K, Gordon R, Mancini J, Riendeau D (2004). Carrageenaninduced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem 279:24866-24872. (Pubitemid 38725355)
12. Hamza M, Dionne RA (2009). Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2:1-14.
13. Hendershot LC, Forsaith J (1958). Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics. J Pharmacol Exp Ther 125:237-240.
14. Iborra M, Moret I, Rausell F, Bastida G, Aguas M, Cerrillo E, et al. (2011). Role of oxidative stress and antioxidant enzymes in Crohn's disease. Biochem Soc Trans 39:1102-1106.
15. Jomova K, Valko M (2011). Advances in metal-induced oxidative stress and human disease. Toxicology 283:65-87.
16. Kopff M, Kopff A, Kowalczyk E (2007). The effect of nonsteroidal anti-inflammatory drugs on oxidative/antioxidative balance. Pol Merk Lek 23:184-187.
17. Lenc?e P (1962). A new device for plethysmoscopic measuring of small objects. Arch Int Pharmacodyn Ther 136:237-240.
18. Litchfield JT, Wilcoxon E (1949). A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113.
19. Lima FO, Souza GR, Verri WA, Parada CA, Ferreira SH, Cunha FQ, Cunha TM (2010). Direct blockade of inflammatory hypernociception by peripheral A1 adenosine receptors: involvement of the NO/cGMP/PKG/KATP signaling pathway. Pain 151:506-515.
20. Malawska B, Gobaille S (1995). Synthesis, physicochemical and pharmacological properties of new N-substituted amides of a-piperazine- ghydroxybutyric acid. Pharmazie 50:390-393.
21. Malawska B, Kulig K, Antkiewicz-Michaluk L, Porter R, Misra A, Cliffe IA (1999). Synthesis, physicochemical properties, anticonvulsant activities, and GABAergic and voltage-sensitive calcium channel receptor affinities of a substituted N-benzylamides of g-hydroxybutyric acid. Part 4: search for new anticonvulsant compounds. Arch Pharm Pharm Med Chem 332:167-174. (Pubitemid 29242636)
22. Malawska B, Kulig K, Gajda J, Szczeblewski D, Musiał A,Wie?ckowski K, Stables JP (2007). Design, synthesis and pharmacological evaluation of a-substituted N-benzylamides of g-hydroxybutyric acid with potential GABA-ergic activity. Part 6. Search for new anticonvulsant compounds. Acta Pol Pharm-Drug Res 64:127-137. (Pubitemid 351356901)
23. McCleane G (2010). Lacosamide for pain. Expert Opin Investig Drugs 19: 1129-1134.
24. Morieux P, Salom C, Duk Park K, Stables JP, Kohn H (2010). The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3 methoxypropionamide. J Med Chem 53:5716-5726.
25. Obon JM, Castellar MR, Cascales JA, Fernandez-Lopez JA (2005). Assessment of the TEAC method for determining the antioxidant capacity of synthetic red food colorants. Food Res Int 38:843-845. (Pubitemid 41080527)
26. Peana AT, De Montis MG, Sechi S, Sircana G, D'Aquila PS, Pippia P (2004). Effects of (-)linalool in the acute hyperalgesia induced by carrageenan, L-glutamate and prostaglandin E2. Eur J Pharmacol 497:279-284. (Pubitemid 39164892)
27. Randall LO, Selitto JJ (1957). A method for measurement of analgesic activity of inflamed tissue. Arch Int Pharmacodyn 111:409-419.
28. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C (1999). Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26:1231-1237. (Pubitemid 29262709)
29. Salat K, Filipek B, Wieckowski K, Malawska B (2009). Analgesic activity of 3-mono substituted derivatives of dihydrofuran-2-one in experimental rodent models of pain. Pharmacol Rep 61:807-818.
30. Salat K, Librowski T, Filipek B (2010). Pharmacological profile of three different gamma butyrolactone derivatives in mice. J Pre-Clin Clin Res 4:14-18.
31. Salat K, Moniczewski A, Salat R, Janaszek M, Filipek B, Malawska B,Wieckowski K (2012). Analgesic, anticonvulsant and antioxidant activity of 3-[4-(3-trifluoromethyl phenyl)-piperazin-1-yl]-dihydrofuran-2-one dihydrochloride in mice. Pharmacol Biochem Behav 101:138-147.
32. Salom C, Salom-Grosjean E, Duk Park K, Morieux P, Swendiman R, De Marco E, Stables JP, Kohn H (2010). Synthesis and anticonvulsant activities of (R)-N-(40-substituted) benzyl 2-acetamido-3-methoxypropionamides. J Med Chem 53:1288-1305.
33. Salvemini D, Little JW, Doyle T, Neumann WL (2011). Roles of reactive oxygen and nitrogen species in pain. Free Radic Biol Med 51:951-966.
34. Shukla V, Mishra SK, Pant HC (2011). Oxidative stress in neurodegeneration. Adv Pharmacol Sci 2011:572-634.
35. Srinivasan V, Pandi-Perumal SR, Spence DW, Moscovitch A, Trakht I, Brown GM, Cardinali DP (2010). Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull 81:362-371.
36. Talarek S, Orzelska J, Listos J, Fidecka S (2010). Effect of sildenafil treatment on the development of tolerance to diazepam-induced motor impairment and sedation in mice. Pharmacol Rep 62:627-634.
37. Wang T, Fu F, Zhang L, Han B, Zhu M, Zhang X (2009). Effects of escin on acute inflammation and the immune system in mice. Pharmacol Rep 61:697-704.
38. Waszkielewicz A, Bojarski J (2004). g-Hydroxybutyric acid (GHB) and its chemical modifications: a review of the GHBergic system. Pol J Pharmacol 56:43-49. (Pubitemid 38515284)
39. Winter CA, Risley EA, Nuss GW (1962). Carrageenin-induced edema in the hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 111:544-547.
40. Wu R, Lamonagne D, de Champlain J (2002). Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 105:387-392. (Pubitemid 34106190)
41. Van den Berg R, Haenen GR, Van den Berg H, Bast A (1999). Applicability of an improved Trolox equivalent antioxidant capacity (TEAC) assay for evaluation of antioxidant capacity measurements of mixtures. Food Chem 66:511-517. (Pubitemid 29255866)
42. Villaño D, Fernández-Pachó n MS, Troncoso AM, Garc?́a-Parrilla MC (2004). The antioxidant activity of wines determined by the ABTSK+ method: influence of sample dilution and time. Talanta 64:501-509.
43. Vogel HG (1997). Drug discovery and evaluation. Pharmacological assays. New York: Springer-Verlag Inc.